S-adenosylmethionine

Last Updated: September 2, 2024

S-adenosylmethionine (SAMe) is a metabolite in the body that helps maintain several important biological reactions. Low levels of SAMe in the body are associated with several conditions, including liver conditions, chronic kidney disease (CKD), coronary artery disease (CAD), depression, and neurodegenerative conditions like dementia and Alzheimer’s disease. Supplementation with SAMe might improve liver health and depression, but further high-quality clinical trials are needed to confirm those benefits.

S-adenosylmethionine is most often used for

What is S-adenosylmethionine?

S-adenosylmethionine is made in the body from ATP and methionine and is produced, broken down, and regenerated in a series of steps known as the SAM (S-adenosylmethionine) cycle.[1][2][3] S-adenosylmethionine circulates in the blood and cerebrospinal fluid, and its major role is as a “methyl donor”, where it provides a methyl group (CH3; three hydrogen atoms attached to a carbon atom) for important biological reactions in the body.[1][2][3] However, it can also donate adenosyl groups, amino groups (NH3), and more in other enzymatic reactions.[4]

S-adenosylmethionine regulates several important biological processes including DNA methylation, immune responses, and amino acid metabolism[1][2][3] and is sold as a food supplement claimed to improve several conditions. In some countries, S-adenosylmethionine is also available as a prescription drug.

What are S-adenosylmethionine’s main benefits?

Low levels of S-adenosylmethionine have been found in people with liver conditions (nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, cirrhosis, etc.),[1][5][6] chronic kidney disease (CKD),[7] coronary artery disease (CAD),[8][9] depression,[10][11][12] and some neurodegenerative conditions like dementia and Alzheimer’s disease.[12][13] These observations suggest that supplementation could help treat such conditions. However, while S-adenosylmethionine has shown therapeutic effects in cell-culture experiments and animal models,[1][5][14] its therapeutic benefit in humans is less convincing.

Current evidence shows that S-adenosylmethionine might help treat depression[15][16][17][18] and might improve liver health and survival in people with liver conditions like cirrhosis.[19][20][21] However, due to the low quality of evidence, further large, double-blind randomized controlled trials are needed to clarify the clinical efficacy of S-adenosylmethionine.

What are S-adenosylmethionine’s main drawbacks?

Despite the popularity of S-adenosylmethionine as a dietary supplement, the main drawback is the lack of high-quality evidence supporting its claimed clinical efficacy (as discussed above). Furthermore, some case studies of patients with underlying conditions have reported serious adverse effects, including manic episodes with suicidal thoughts.[22][23][24][25] For this reason, people with bipolar disorder should consult their doctor before considering using S-adenosylmethionine.

Other studies have reported side effects including headaches, insomnia, and nausea,[26][15][27] while further studies have highlighted safety concerns when S-adenosylmethionine is consumed in excess.[28] However, adverse effects are rare and side effects are uncommon, so S-adenosylmethionine is generally considered safe to consume.[24][26][15][27] That said, Cochrane reviews on S-adenosylmethionine note that studies in this field rarely document adverse events.[15][27]

How does S-adenosylmethionine work?

S-adenosylmethionine regulates biological processes by transferring methyl groups, adenosyl groups, amino groups, and more to proteins, lipids, nucleic acids (e.g., DNA), and several other metabolites in many enzymatic reactions.[1][4][2][3]

Because several conditions — liver disease, kidney disease, heart disease, and neurodegenerative conditions, etc. — are associated with low levels of S-adenosylmethionine in blood or tissues,[1][5][6][7][8][9][12][13] supplementation might help restore normal levels. However, even if this is possible, the evidence supporting the therapeutic efficacy of supplementation with S-adenosylmethionine is weak (as described above).

What are other names for S-adenosylmethionine?
Note that S-adenosylmethionine is also known as:
  • SAM
  • SAMe
  • SAM-e
  • Adomet
  • Ademetionine
  • S-adenosyl-L-methionine
S-adenosylmethionine should not be confused with:
  • Methionine
Dosage information

Formulations: Tablets taken orally, or liquid injected intravenously or intramuscularly.

Range of dosages studied: 45 to 3200 milligrams per day (mg/day).

Dosage recommendation: In some studies, the dosage range that has been found to improve depression is approximately 200 to 1,600 mg/day. In some studies, the dosage range that has been found to improve liver health in people with chronic liver conditions is approximately 800 to 1,200 mg/day

Take with food: S-adenosylmethionine can be taken with or without food.

Safety information:

S-adenosylmethionine can interact with several drugs including drugs that affect serotonin, including Selective Serotonin Reuptake Inhibitors and Monoamine Oxidase Inhibitors. Due to the increased risk of mania, S-adenosylmethionine is not recommended for people with bipolar disorder.

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Examine Database: S-adenosylmethionine
What works and what doesn't?

Unlock the full potential of Examine

Get started

Don't miss out on the latest research

Update History
9 days ago

Full page update

major

This page was updated on 08/2024.  There were no existing FAQs on this page so the following standard FAQs were added:

What is S-adenosylmethionine?

What are S-adenosylmethionine's main benefits?

What are S-adenosylmethionine's main drawbacks?

How does S-adenosylmethionine work?

Additionally, the following additional FAQs were added: What is the SAM cycle? What are the pharmacokinetics of S-adenosylmethionine? Does S-adenosylmethionine treat osteoarthritis?

We added 7 new meta-analyses to the Examine database. These additions caused the following changes:

“Osteoarthritis Symptoms” has been changed from a “moderate improvement” to a “no improvement” because while some small older trials that lack a placebo group show SAM to be as effective as other drugs in managing pain for osteoarthritis, meta-analyses of trials comparing SAM to placebo do not find improvements in pain or function associated with osteoarthritis.

“Depression Symptoms” has been changed from a “moderate improvement” to a “small improvement”.

Written By

Reviewed By

References
  1. ^Pascale RM, Simile MM, Calvisi DF, Feo CF, Feo FS-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent.Cells.(2022 Jan 25)
  2. ^Fontecave M, Atta M, Mulliez ES-adenosylmethionine: nothing goes to waste.Trends Biochem Sci.(2004 May)
  3. ^Mato JM, Alvarez L, Ortiz P, Pajares MAS-adenosylmethionine synthesis: molecular mechanisms and clinical implications.Pharmacol Ther.(1997)
  4. ^Lee YH, Ren D, Jeon B, Liu HWS-Adenosylmethionine: more than just a methyl donor.Nat Prod Rep.(2023 Sep 20)
  5. ^Lu SC, Mato JMS-adenosylmethionine in liver health, injury, and cancer.Physiol Rev.(2012 Oct)
  6. ^Robinson AE, Binek A, Ramani K, Sundararaman N, Barbier-Torres L, Murray B, Venkatraman V, Kreimer S, Ardle AM, Noureddin M, Fernández-Ramos D, Lopitz-Otsoa F, Gutiérrez de Juan V, Millet O, Mato JM, Lu SC, Van Eyk JEHyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency.iScience.(2023 Feb 17)
  7. ^Kruglova MP, Grachev SV, Bulgakova PO, Ivanov AV, Virus ED, Nikiforova KA, Fedoseev AN, Savina GD, Kubatiev AALow S-adenosylmethionine/ S-adenosylhomocysteine Ratio in Urine is Associated with Chronic Kidney Disease.Lab Med.(2020 Jan 2)
  8. ^Liu S, Liao R, Dai X, Guo H, Wang D, Xia M, Ling W, Xiao YAssociation between plasma S-adenosylmethionine and risk of mortality in patients with coronary artery disease: A cohort study.Am J Clin Nutr.(2021 Oct 4)
  9. ^Loehrer FM, Angst CP, Haefeli WE, Jordan PP, Ritz R, Fowler BLow whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease.Arterioscler Thromb Vasc Biol.(1996 Jun)
  10. ^Papakostas GI, Alpert JE, Fava MS-adenosyl-methionine in depression: a comprehensive review of the literature.Curr Psychiatry Rep.(2003 Dec)
  11. ^T Bottiglieri, P Godfrey, T Flynn, M W Carney, B K Toone, E H ReynoldsCerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionineJ Neurol Neurosurg Psychiatry.(1990 Dec)
  12. ^T Bottiglieri, K HylandS-adenosylmethionine levels in psychiatric and neurological disorders: a reviewActa Neurol Scand Suppl.(1994)
  13. ^L D Morrison, D D Smith, S J KishBrain S-adenosylmethionine levels are severely decreased in Alzheimer's diseaseJ Neurochem.(1996 Sep)
  14. ^Sarah E Montgomery, Amir A Sepehry, John D Wangsgaard, Jeremy E KoenigThe effect of S-adenosylmethionine on cognitive performance in mice: an animal model meta-analysisPLoS One.(2014 Oct 27)
  15. ^Ilaria Galizia, Lucio Oldani, Karine Macritchie, Erica Amari, Dominic Dougall, Tessa N Jones, Raymond W Lam, Guido Jacopo Massei, Lakshmi N Yatham, Allan H YoungS-adenosyl methionine (SAMe) for depression in adultsCochrane Database Syst Rev.(2016 Oct 10)
  16. ^Limveeraprajak N, Nakhawatchana S, Visukamol A, Siripakkaphant C, Suttajit S, Srisurapanont MEfficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis.Prog Neuropsychopharmacol Biol Psychiatry.(2024 Jun 8)
  17. ^Peng TR, Cheng HY, Wu TWS-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis.Gen Hosp Psychiatry.(2024 Jan-Feb)
  18. ^Cuomo A, Beccarini Crescenzi B, Bolognesi S, Goracci A, Koukouna D, Rossi R, Fagiolini AS-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review.Ann Gen Psychiatry.(2020)
  19. ^Tao Guo, Lei Chang, Yusha Xiao, Quanyan LiuS-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysisPLoS One.(2015 Mar 16)
  20. ^Mato JM, Cámara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, García-Buey L, Beltrán J, Benita V, Caballería J, Solà R, Moreno-Otero R, Barrao F, Martín-Duce A, Correa JA, Parés A, Barrao E, García-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodés JS-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.J Hepatol.(1999 Jun)
  21. ^Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JGPharmacological interventions for treating intrahepatic cholestasis of pregnancy.Cochrane Database Syst Rev.(2020 Jul 27)
  22. ^Chitiva H, Audivert F, Alvarez CSuicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report.J Nerv Ment Dis.(2012 Jan)
  23. ^Berigan TRA Case Report of a Manic Episode Triggered by S-Adenosylmethionine (SAMe).Prim Care Companion J Clin Psychiatry.(2002 Aug)
  24. ^Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BMBioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humansPharmacotherapy.(2004 Nov)
  25. ^Abeysundera H, Gill RPossible SAMe-induced mania.BMJ Case Rep.(2018 Jun 27)
  26. ^Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle PS-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease.Evid Rep Technol Assess (Summ).(2003 Aug)
  27. ^Rutjes AW, Nüesch E, Reichenbach S, Jüni PS-Adenosylmethionine for osteoarthritis of the knee or hip.Cochrane Database Syst Rev.(2009 Oct 7)
  28. ^Fukumoto K, Ito K, Saer B, Taylor G, Ye S, Yamano M, Toriba Y, Hayes A, Okamura H, Fustin JMExcess S-adenosylmethionine inhibits methylation via catabolism to adenine.Commun Biol.(2022 Apr 5)
  29. ^Clare CE, Brassington AH, Kwong WY, Sinclair KDOne-Carbon Metabolism: Linking Nutritional Biochemistry to Epigenetic Programming of Long-Term Development.Annu Rev Anim Biosci.(2019-Feb-15)
  30. ^Stramentinoli G, Catto EPharmacokinetic studies of S-adenosyl-L-methionine (SAMe) in several animal species.Pharmacol Res Commun.(1976 Apr)
  31. ^Giulidori P, Cortellaro M, Moreo G, Stramentinoli GPharmacokinetics of S-adenosyl-L-methionine in healthy volunteers.Eur J Clin Pharmacol.(1984)
  32. ^Friedel HA, Goa KL, Benfield PS-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism.Drugs.(1989 Sep)
  33. ^Yang J, He Y, Du YX, Tang LL, Wang GJ, Fawcett JPPharmacokinetic properties of S-adenosylmethionine after oral and intravenous administration of its tosylate disulfate salt: a multiple-dose, open-label, parallel-group study in healthy Chinese volunteers.Clin Ther.(2009 Feb)
  34. ^G StramentinoliPharmacologic aspects of S-adenosylmethionine. Pharmacokinetics and pharmacodynamicsAm J Med.(1987 Nov 20)
  35. ^Beth R Cameron, Ludvina Ferreira, I David MacDonaldPharmacokinetic study of a novel oral formulation of S-adenosylmethionine (MSI-195) in healthy subjects: dose escalation, food effect and comparison to a commercial nutritional supplement productBMC Pharmacol Toxicol.(2020 Dec 14)
  36. ^Antonio Francioso, Sergio Fanelli, Maria d'Erme, Eugenio Lendaro, Niccolò Miraglia, Mario Fontana, Rosaria A Cavallaro, Luciana MoscaPharmacokinetic properties of a novel formulation of S-adenosyl-L-methionine phytateAmino Acids.(2021 Oct)
  37. ^Gulin Amasya, Ahmet Dogan Ergin, Ozge Erkan Cakirci, Arif Tanju Ozçelikay, Zerrin Sezgin Bayindir, Nilufer YukselA study to enhance the oral bioavailability of s-adenosyl-l-methionine (SAMe): SLN and SLN nanocomposite particlesChem Phys Lipids.(2021 Jul)
Examine Database References
  1. Homocysteine - F M Loehrer, R Schwab, C P Angst, W E Haefeli, B FowlerInfluence of oral S-adenosylmethionine on plasma 5-methyltetrahydrofolate, S-adenosylhomocysteine, homocysteine and methionine in healthy humansJ Pharmacol Exp Ther.(1997 Aug)
  2. Homocysteine - Thompson MA, Bauer BA, Loehrer LL, Cha SS, Mandrekar JN, Sood A, Wahner-Roedler DLDietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trialJ Altern Complement Med.(2009 May)
  3. Homocysteine - Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BMBioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humansPharmacotherapy.(2004 Nov)
  4. Depression Symptoms - A Di Rocco, J D Rogers, R Brown, P Werner, T BottiglieriS-Adenosyl-Methionine improves depression in patients with Parkinson's disease in an open-label clinical trialMov Disord.(2000 Nov)
  5. Osteoarthritis Symptoms - Soeken KL, Lee WL, Bausell RB, Agelli M, Berman BMSafety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritisJ Fam Pract.(2002 May)
  6. Osteoarthritis Symptoms - Kim J, Lee EY, Koh EM, Cha HS, Yoo B, Lee CK, Lee YJ, Ryu H, Lee KH, Song YWComparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patientsClin Ther.(2009 Dec)
  7. Osteoarthritis Symptoms - Caruso I, Pietrogrande VItalian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint diseaseAm J Med.(1987 Nov 20)
  8. Osteoarthritis Symptoms - Wadie I Najm, Sibylle Reinsch, Fred Hoehler, Jerome S Tobis, Phillip W HarveyS-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]BMC Musculoskelet Disord.(2004 Feb 26)
  9. Osteoarthritis Symptoms - Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle PS-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease.Evid Rep Technol Assess (Summ).(2003 Aug)
  10. Osteoarthritis Symptoms - Rutjes AW, Nüesch E, Reichenbach S, Jüni PS-Adenosylmethionine for osteoarthritis of the knee or hip.Cochrane Database Syst Rev.(2009 Oct 7)
  11. Fibromyalgia Symptoms - Jacobsen S, Danneskiold-Samsøe B, Andersen RBOral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluationScand J Rheumatol.(1991)
  12. Liver Fibrosis - Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory JF 3rd, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, Halsted CHS-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trialAlcohol Clin Exp Res.(2011 Nov)
  13. Cholestasis - Binder T, Salaj P, Zima T, Vítek LRandomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancyJ Perinat Med.(2006)
  14. Cholestasis - Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JGPharmacological interventions for treating intrahepatic cholestasis of pregnancy.Cochrane Database Syst Rev.(2020 Jul 27)
  15. Depression Symptoms - Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava MS-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trialAm J Psychiatry.(2010 Aug)
  16. Depression Symptoms - Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon DS-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of responseJ Affect Disord.(2014 Aug)
  17. Depression Symptoms - Ilaria Galizia, Lucio Oldani, Karine Macritchie, Erica Amari, Dominic Dougall, Tessa N Jones, Raymond W Lam, Guido Jacopo Massei, Lakshmi N Yatham, Allan H YoungS-adenosyl methionine (SAMe) for depression in adultsCochrane Database Syst Rev.(2016 Oct 10)
  18. Depression Symptoms - Peng TR, Cheng HY, Wu TWS-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis.Gen Hosp Psychiatry.(2024 Jan-Feb)
  19. Depression Symptoms - Limveeraprajak N, Nakhawatchana S, Visukamol A, Siripakkaphant C, Suttajit S, Srisurapanont MEfficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis.Prog Neuropsychopharmacol Biol Psychiatry.(2024 Jun 8)
  20. Attention - Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GIEffects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorderJ Affect Disord.(2012 Feb)
  21. Early Virologic Response - Jordan J Feld, Apurva A Modi, Ramy El-Diwany, Yaron Rotman, Emmanuel Thomas, Golo Ahlenstiel, Rachel Titerence, Christopher Koh, Vera Cherepanov, Theo Heller, Marc G Ghany, Yoon Park, Jay H Hoofnagle, T Jake LiangS-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonrespondersGastroenterology.(2011 Mar)
  22. Liver Enzymes - Santini D, Vincenzi B, Massacesi C, Picardi A, Gentilucci UV, Esposito V, Liuzzi G, La Cesa A, Rocci L, Marcucci F, Montesarchio V, Groeger AM, Bonsignori M, Tonini GS-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injuryAnticancer Res.(2003 Nov-Dec)
  23. Bilirubin - Tao Guo, Lei Chang, Yusha Xiao, Quanyan LiuS-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysisPLoS One.(2015 Mar 16)